RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (RespireRx or the Company), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Companys senior management will participate in the following virtual investor conference in June 2021:
- Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (RespireRx or the Company), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that the Companys senior management will participate in the following virtual investor conference in June 2021:
Access China Biotech 2021 Digital (June 9-14, 2021)
The Access China Biotech Forumis a quarterly corporate access event series between China and Western biopharma. - We believe that the medical and patient community are in clear agreement that there is desperate need for improved antiepileptic drugs.
- From our AMPAkine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
- At present, the major pharmacotherapies available for ADHD are made up of two types of drugs.